Avadel CNS v. Jazz Pharmaceuticals: XYWAV GHB Patent Dispute Settled With Prejudice
Avadel CNS Pharmaceuticals filed suit against Jazz Pharmaceuticals in Delaware over US12186298B2, a patent covering gamma-hydroxybutyrate oral solution formulations tied to XYWAV. The parties reached a confidential settlement and stipulated to dismissal with prejudice after 286 days — closing all claims and counterclaims between the two narcolepsy drug rivals.
GHB narcolepsy patent clash ends in confidential settlement
Avadel CNS Pharmaceuticals LLC filed this infringement action on 14 January 2025 in the District of Delaware before Judge Gregory B. Williams, asserting US12186298B2 against Jazz Pharmaceuticals Inc. The patent relates to oral solution formulations containing salts of gamma-hydroxybutyrate (GHB), the active ingredient in XYWAV — Jazz’s lower-sodium oxybate product approved for narcolepsy. Avadel, itself a commercialiser of LUMRYZ (a once-nightly sodium oxybate formulation), and Jazz are well-established adversaries in the GHB sleep-disorder drug space.
The case closed on 27 October 2025 via a joint stipulation of dismissal with prejudice under Federal Rules of Civil Procedure 41(a)(1)(A)(ii) and/or 41(a)(2), reached pursuant to a confidential settlement agreement. All claims and counterclaims between Avadel CNS Pharmaceuticals LLC, Avadel Pharmaceuticals plc, Flamel Ireland Limited, Jazz Pharmaceuticals Inc., and Jazz Pharmaceuticals Ireland Limited were extinguished. Each party was left responsible for its own legal costs, suggesting a negotiated resolution rather than a one-sided capitulation.
At 286 days, the matter resolved before any substantive merits ruling — consistent with the pattern of prior Avadel–Jazz litigation, which has involved multiple parallel actions and cross-licensing dynamics in the oxybate space. The specific settlement terms, including any licensing, royalty, or market-access provisions, remain confidential and are not reflected in the public record. The dismissal with prejudice bars Avadel from reasserting the same patent claims against Jazz in future proceedings.
Filing to Dismissed with Prejudice in 286 days
286 days from filing to dismissal — consistent with pre-trial settlement timelines in Delaware pharmaceutical patent disputes
Dismissed with prejudice: what the stipulated settlement means for both parties
Rule 41 dismissal with prejudice — all claims permanently closed
A stipulated dismissal with prejudice under Fed. R. Civ. P. 41(a)(1)(A)(ii) or 41(a)(2) operates as a final adjudication on the merits. Neither Avadel nor Jazz can revive the same claims or counterclaims in a new action. The parties’ settlement agreement — though confidential — is the commercial instrument giving effect to this permanent resolution. No court order on the patent’s validity or infringement was issued.
Permanent bar on re-filingAvadel trades litigation rights for confidential settlement terms
By agreeing to dismissal with prejudice, Avadel CNS foregoes the right to re-assert US12186298B2 against Jazz in this dispute. The patent itself remains in force and enforceable against third parties. What Avadel received in exchange — whether a licence, a payment, or market-access terms — is not disclosed in the public record. The outcome is consistent with a negotiated resolution rather than a defeat on the merits.
Patent survives; claims extinguishedJazz secures certainty on XYWAV without a validity ruling
Jazz achieves closure on this specific action without any judicial finding that XYWAV infringes US12186298B2 or that the patent is valid. The confidential settlement likely provides Jazz with defined commercial terms or freedom-to-operate certainty for XYWAV. However, the absence of a merits ruling means the patent’s validity and scope remain untested — potentially relevant if related claims arise in other proceedings.
No infringement or validity findingGHB oxybate IP landscape remains actively contested post-settlement
The Avadel–Jazz oxybate rivalry has generated multiple patent actions across several years. This settlement closes one front but does not resolve the broader IP landscape around low-sodium GHB formulations. Companies developing generic or novel oxybate products should note that US12186298B2 remains an active, enforceable patent. The symmetric cost-bearing arrangement suggests neither party extracted a clear concession — or that terms were balanced enough to avoid fee-shifting arguments.
Oxybate IP landscape still activeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Avadel CNS Pharmaceuticals, LLC | Company | CNS pharmaceutical company — holder of US12186298B2 covering GHB oral solution formulationsSearch in Eureka ↗ |
| Defendant | Jazz Pharmaceuticals, Inc. | Company | Jazz Pharmaceuticals Inc. — originator and marketer of XYWAV low-sodium oxybate oral solutionSearch in Eureka ↗ |
| Plaintiff counsel | Adam R. Brausa | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Alex M. Grabowski | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daralyn J. Durie | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Herman H. Yue | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kelly Welsh | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kenneth G. Schuler | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kira A. Davis | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Manuela Burek | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Marc N. Zubick | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Ramya Sri Vallabhaneni | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | Cameron Paul Clark | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeremy A. Tigan | Attorney | Counsel for Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Jazz Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal with prejudice extinguishes all claims and counterclaims between the named Avadel and Jazz entities by agreement — not by judicial ruling on the merits. The explicit invocation of Rule 41(a)(1)(A)(ii) and/or 41(a)(2) confirms the procedural vehicle, while the ‘with prejudice’ designation is the operative legal consequence: Avadel cannot re-file. The symmetric cost-bearing clause is commercially significant — it forecloses any subsequent fee-shifting motion and reflects a mutually acceptable resolution.
US12186298B2 — GHB oral solution formulation for narcolepsy treatment
US12186298B2, filed under application number US18/758081, covers oral solution formulations containing salts of gamma-hydroxybutyrate (GHB) — the pharmacologically active compound in both XYWAV and LUMRYZ. GHB-based drugs are FDA-approved for treating cataplexy and excessive daytime sleepiness in narcolepsy patients. The patent’s claims are directed at the composition and formulation layer of these products, placing it squarely within the contested IP space surrounding low-sodium oxybate drug development.
In a market where Avadel’s LUMRYZ (once-nightly GHB) competes directly with Jazz’s XYWAV (twice-nightly, lower-sodium GHB), formulation patents carry significant commercial leverage. US12186298B2 represents one asset in what is likely a broader Avadel formulation portfolio. For companies developing generic or next-generation oxybate therapies, this patent presents a non-trivial clearance challenge — particularly given Avadel’s demonstrated enforcement posture across multiple Delaware actions against Jazz.
Should you run an FTO against US12186298B2 before entering the oxybate market?
Any company developing an oral GHB or oxybate salt formulation — whether as an ANDA filer, a novel NDA applicant, or a reformulation programme — should conduct a formal freedom-to-operate analysis against US12186298B2 before advancing to clinical or regulatory stages. The patent remains in force and enforceable following this settlement. The dismissal with prejudice affects only Avadel’s claims against Jazz — it provides no legal insulation for third parties.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map product candidates against US12186298B2’s claim scope, identify relevant prior art, and flag claim-overlap risks early in development. Eureka can also surface related Avadel patents in the GHB formulation space — giving product teams a portfolio-level view of clearance risk, not just single-patent exposure. This is particularly valuable before ANDA filing or IND submission in the narcolepsy drug space.
Run a freedom-to-operate analysis on US12186298B2 to assess your product’s exposure
Run FTO in Eureka →Similar GHB formulation patent disputes in Delaware District Court
Explore related oxybate and CNS drug formulation patent infringement cases filed in Delaware District Court involving Avadel, Jazz, and competing GHB product developers.
What this case signals for the CNS oxybate IP landscape
The Avadel–Jazz settlement continues a pattern of negotiated resolution in GHB drug patent litigation — with key implications for oxybate market entrants.
US12186298B2 remains enforceable against third-party oxybate developers
The dismissal with prejudice binds only Avadel and Jazz. US12186298B2 is fully valid and enforceable against any other party developing GHB oral solution formulations. Generic oxybate developers and biosimilar entrants should treat this patent as an active litigation risk requiring formal FTO analysis before product launch.
Symmetric cost-bearing suggests a balanced settlement — not a unilateral win
When each party bears its own legal costs, it typically signals that neither side extracted a dominant commercial concession. In high-stakes pharmaceutical patent disputes, fee-bearing symmetry is often a deliberate negotiating signal. The public record does not reveal royalty flows, licensing terms, or market-access provisions — these remain commercially sensitive.
Avadel v Jazz — key questions answered
The case was dismissed with prejudice on 27 October 2025 pursuant to a confidential settlement agreement. All claims and counterclaims between Avadel CNS Pharmaceuticals LLC, Avadel Pharmaceuticals plc, Flamel Ireland Limited, and Jazz Pharmaceuticals Inc. and Jazz Pharmaceuticals Ireland Limited were extinguished. Each party bore its own attorneys’ fees and costs.
Avadel CNS asserted US12186298B2 (application no. US18/758081), a patent covering oral solution formulations containing salts of gamma-hydroxybutyrate. The patent relates to the active formulation chemistry underlying XYWAV, Jazz’s low-sodium oxybate oral solution approved for narcolepsy.
Dismissal with prejudice permanently bars Avadel from re-filing the same claims against Jazz Pharmaceuticals in connection with this dispute. However, patent US12186298B2 itself remains valid and enforceable — Avadel retains the right to assert it against other parties. The dismissal is a litigation closure mechanism, not a ruling on the patent’s validity or infringement scope.
No. The case resolved via stipulated dismissal under Rule 41 before any merits ruling was issued. The court made no determination on whether Jazz’s XYWAV infringes US12186298B2, nor on the patent’s validity. The settlement terms, which govern the commercial resolution between the parties, remain confidential.
Avadel and Jazz are the two principal competitors in the branded oxybate market for narcolepsy, with LUMRYZ and XYWAV as their respective products. Patent litigation between them directly affects exclusivity timelines, generic entry risk, and licensing dynamics in a market where GHB formulation IP is actively contested. This settlement closes one action but leaves the broader patent landscape — including Avadel’s formulation portfolio — active and relevant for any new market entrant.
PatSnap Eureka searches patents and litigation data to answer instantly.